Chinese Peptide Company: difference between revisions
Diff·revision 33 → 34·14:49, 2 Jan 2025
Difference between revision 33 and revision 34 of Chinese Peptide Company. 10 lines changed; the page grew by 638 bytes.
| Revision 33 — 14:42, 27 Dec 2024 LedgerLysander (talk) expand §Operations and documentation practice 6,920 bytes ±0 | Revision 34 — 14:49, 2 Jan 2025 VerifyFirstVida (talk) rm unsourced claim per PP:V 7,558 bytes +638 | ||
|---|---|---|---|
| 49 | The presence of a custom-synthesis line is the distinguishing catalogue feature. A supplier that will synthesise an arbitrary sequence is doing something different from one that lists a fixed range, and the two should not be described in the same terms.{{r|selfpub}} | 49 | The presence of a custom-synthesis line is the distinguishing catalogue feature. A supplier that will synthesise an arbitrary sequence is doing something different from one that lists a fixed range, and the two should not be described in the same terms.{{r|selfpub}} |
| 50 | 50 | ||
| + | 51 | == Independent testing record == | |
| + | 52 | Reports submitted on CPC material to July 2026 span a wider set of analytes than for most organisations covered here, including several sequences outside the incretin range. Reported [[Area percent purity|area percent]] figures have been high, and in the subset where the certificate reported both purity and water, purchaser-computed [[Peptide content|peptide content]] figures have been consistent with the certificate's own arithmetic.{{r|reports,usp1503}} | |
| + | 53 | ||
| 51 | == References == | 54 | == References == |
| 52 | {{reflist}} | 55 | {{reflist}} |
| ⋮ | ⋮ | ||
| 57 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 60 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| 58 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 61 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 62 | ||
| + | 63 | == See also == | |
| + | 64 | * [[Certificate of analysis]] | |
| + | 65 | * [[Third-party testing]] | |
| + | 66 | * [[Area percent purity]] | |
| + | 67 | * [[Peptide content]] | |
| + | 68 | * [[Research use only]] | |
| 59 | 69 | ||
| 60 | {{DEFAULTSORT:Chinese Peptide Company}} | 70 | {{DEFAULTSORT:Chinese Peptide Company}} |